JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

101.13 -1.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

101.02

Max

101.42

Belangrijke statistieken

By Trading Economics

Inkomsten

123M

795M

Verkoop

398M

5.1B

K/W

Sectorgemiddelde

59.135

37.461

Winstmarge

15.708

Werknemers

53,000

EBITDA

155M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+25.06% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.6B

149B

Vorige openingsprijs

102.37

Vorige sluitingsprijs

101.13

Nieuwssentiment

By Acuity

30%

70%

68 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2025, 11:00 UTC

Winsten

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17 okt 2025, 11:43 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23 jul 2025, 11:16 UTC

Winsten

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22 okt 2025, 10:32 UTC

Winsten

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 okt 2025, 10:32 UTC

Winsten

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 okt 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 okt 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific 3Q Adj EPS 75c >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific 3Q Sales $5.07B >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific 3Q EPS 51c >BSX

22 okt 2025, 10:30 UTC

Winsten

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17 okt 2025, 11:02 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17 okt 2025, 11:02 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17 okt 2025, 11:01 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17 okt 2025, 11:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9 sep 2025, 12:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 sep 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 jul 2025, 10:32 UTC

Winsten

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 jul 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q EPS 53c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Sales $5.06B >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Adj EPS 75c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

25.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 126.45 USD  25.06%

Hoogste 140 USD

Laagste 113 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

24 ratings

23

Buy

1

Hold

0

Sell

Technische score

By Trading Central

102.95 / 104.93Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

68 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat